Well, it’s taken a little over 2 years, but OncoGenex has completed enrollment of patients into the randomized, double-blind, Phase III SYNERGY trial, which is designed to assess whether the addition of custirsen (OGX-011) to docetaxel-based chemotherapy can extend the survival of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development | Tagged: custirsen, mCRPC, OGX-011, Phase III, trial | 6 Comments »
The Phase III SATURN clinical trial of OGX-011 in treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after initial chemotherapy with docetaxel + prednisone required men to be randomized to either docetaxel + prednisone + OGX-011 or to docetaxel + prednisone + a placebo. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, custirsen, docetaxel, OGX-011, pain, SATURN, survival, synergy | Leave a comment »
So lots of posters and and presentations this morning, but not a lot of actionable information for patients (as far a we could tell). Among the more interesting papers were the following: … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Gleason score, MDV3100, mortality, OGX-011, positive, risk, surgical. margin | Leave a comment »
Back in 2009 we reported the results of a randomized Phase II trial of docetaxel + OGX-011 vs. docetaxel + placebo as they were initially presented at the annual meeting of the American Society of Clinical Oncology in Chicago (ASCO). … READ MORE …
Filed under: Drugs in development | Tagged: CRPC, custirsen, OGX-011 | Leave a comment »
OncoGenex has initiated the first of two Phase III trials of custirsen sodium (OGX-011) in the treatment of men with metastatic castrate-resistant prostate cancer (mCPRC). … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: castration-resistant, custirsen, mCRPC, OGX-011, OncoGenex | Leave a comment »
In a somewhat surprising announcement, Teva Pharmaceuticals — best known as the world’s largest manufacturer and marketer of generic drugs — has acquired the global development and marketing rights to OGX-011 from OncoGenex. … READ MORE …
Filed under: Drugs in development | Tagged: OGX-011, OncoGenex, Teva | Leave a comment »
For readers who are interested in OncoGenex Pharmaceuticals‘ plans for the future development of Phase III trial of OGX-011 (an antisense compound that acts as a clusterin growth inhibitor), it’s worth reading Luke Timmerman’s article on Xconomy.com, which is based on a recent interview with OncoGenex’s CEO, Scott Cormack. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant prostate cancer, CRPC, OGX-011 | Leave a comment »
On Saturday there were two major prostate cancer sessions and additional poster sessions that included prostate cancer-related material at the annual meeting of the American Society for Clinical Oncology. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: MDV3100, OGX-011, PROSTVAC-VF, vaccines | Leave a comment »
In the past two days, data has been made available from Phase II trials suggesting the potential of the AstraZeneca endothelin antagonist ZD4054 and Oncogenex’s resistance inhibitor OGX-011 in the treatment of hormone-refractory prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: OGX-011, ZD4054 | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 